Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Interleukin-2 in Soft Tissue Melanoma Metastases
NCT00204581Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Aug 2003
- Primary completion
- Jan 2009
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in melanoma, sponsored by University Hospital Tübingen. Primary endpoint: Objective Response Rate at 4 weeks. Started Aug 2003; status: completed.
02
Drugs
aldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00204581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00204581.